IP Library › Granted Patent US 8,754,225
Granted Patent B2
US 8,754,225 · App. 13/173,274 · Granted Jun 17, 2014

Process for preparing a biphenyl-2-ylcarbamic acid

Inventor: Pierre-Jean Colson (San Francisco, CA)
Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,754,225
App. No.
13/173,274
Granted
Jun 17, 2014
Kind
B2
Abstract

The invention provides a process of preparing an intermediate useful in the synthesis of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and a process of preparing a crystalline freebase of the ester.

Claims (13)

1. A process for preparing a crystalline freebase (Form III) of the compound of formula I:

the process comprising the steps of:

(a) coupling a compound of formula 8:

with a compound of formula 9:

in the presence of a coupling reagent to yield the compound of formula 10:

(b) reductive amination of the compound of formula 10 and a compound of formula 11:

in the presence of a reducing agent to yield the compound of formula I, wherein azeotropic distillation of water is conducted at an elevated temperature prior to the addition of the reducing agent, and reductive amination is conducted at room temperature;

(c) contacting the product of step (b) with isopropyl acetate, optionally adding a seed crystal of the crystalline freebase (Form III) to form a solid, and isolating the resulting solid; and

(d) contacting the product of step (c) with toluene, optionally adding a seed crystal of the crystalline freebase (Form III) to form a solid, and isolating the resulting solid as the crystalline freebase (Form III); wherein step (a) and step (b) are conducted in the same reaction mixture without isolation of the intermediate from step (a).

2. The process of claim 1 , wherein step (a) is conducted in methyltetrahydrofuran.

3. The process of claim 1 , wherein the coupling reagent in step (a) is a 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium compound.

4. The process of claim 1 , wherein the elevated temperature in step (b) is within the range of about 40-70° C.

5. The process of claim 1 , wherein the reducing agent in step (b) is sodium triacetoxyborohydride.

Assignments (3)
SECURITY INTEREST Recorded Sep 24, 2026
From: THERAVANCE BIOPHARMA R&D IP, LLC
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 076134/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 033135/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2011
From: COLSON, PIERRE-JEAN
To: THERAVANCE, INC.
Reel/Frame 026529/0508 →
Continuity (2)
Provisional Application 61363725 · Jul 13, 2010
Related Publication 20120016130A1 · Jan 19, 2012